van Gelder M, Mulder A H, van Bekkum D W
Introgene B.V., Rijswijk, The Netherlands.
Transplantation. 1996 Sep 27;62(6):810-8. doi: 10.1097/00007890-199609270-00019.
BUF rats suffering from severe relapsing experimental autoimmune encephalomyelitis (R-EAE), a model for multiple sclerosis, were treated with intensive cytoreductive therapy and grafting of allogeneic bone marrow (BM). BN.1B rats were used as EAE-resistant, largely MHC-matched donors, resembling human BMT from HLA-identical siblings. The treatment induces complete remission and low recurrence rates of R-EAE. Evidence is provided that the efficacy of the treatment depends on a high degree of lymphoablation: a minority of rats had host-type residual activated T lymphocytes in the CNS after treatment. Furthermore, complete replacement of host-type BM by donor-type hemopoietic cells is essential, as higher relapse rates were observed in animals with incomplete reconstitution by donor cells than in completely reconstituted rats. Overall, our results indicate that patients with severe MS might benefit from treatment with HLA-matched allogeneic BM.
患有严重复发性实验性自身免疫性脑脊髓炎(R-EAE,一种多发性硬化症模型)的BUF大鼠接受了强化细胞减灭疗法和同种异体骨髓移植。BN.1B大鼠用作EAE抗性、主要是MHC匹配的供体,类似于来自HLA相同同胞的人类骨髓移植。该治疗可诱导R-EAE完全缓解且复发率低。有证据表明,治疗效果取决于高度的淋巴细胞清除:少数大鼠在治疗后中枢神经系统中存在宿主型残留活化T淋巴细胞。此外,供体型造血细胞完全替代宿主型骨髓至关重要,因为与完全重建的大鼠相比,供体细胞重建不完全的动物复发率更高。总体而言,我们的结果表明,重度多发性硬化症患者可能受益于HLA匹配的同种异体骨髓治疗。